PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T‐cell infiltration

• Published in: Journal of cellular and molecular medicine 2023-03, Vol.27 (5), p.609-621
• Main Authors: Wang, Xiaomin, Fang, Aizhong, Peng, Yichen, Yu, Jianyu, Yu, Chunna, Xie, Jinxuan, Zheng, Yi, Song, Lairong, Li, Parker, Li, Jia, Kang, Xun, Lin, Yi, Li, Wenbin
• Format: Article
• Language: English
• Subjects: Antibodies; Biomarkers; Cancer; Carcinoma; Carcinoma, Endometrioid - genetics; CD3 antigen; Cell cycle; Cell migration; Cell proliferation; clinical outcome; Datasets; Endometrial cancer; Endometrial Neoplasms - pathology; Endometrium; Epigenesis, Genetic; epigenetic regulated gene; Epigenetics; Female; gene regulation; Homeobox; Humans; immune infiltration; Infiltration; Leukemia; Lymphocytes; Lymphocytes T; Medical prognosis; Metastases; Mutation; Neoplasm Recurrence, Local - genetics; Original; PHF6; Protein expression; Proteins; Repressor Proteins - genetics; Reproductive system; Survival analysis; T-Lymphocytes - metabolism; Uterine cancer; uterine corpus endometrial carcinoma; Uterus - metabolism
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.17638

Uterine corpus endometrial carcinoma (UCEC) is the most common cancer of the female reproductive tract. The overall survival of advanced and recurrent UCEC patients is still unfavourable nowadays. It is urgent to find a predictive biomarker and block tumorgenesis at an early stage. Plant homeodomain finger protein 6 (PHF6) is a key player in epigenetic regulation, and its alterations lead to various diseases, including tumours. Here, we found that PHF6 expression was upregulated in UCEC tissues compared with normal tissues. The UCEC patients with high PHF6 expression had poor survival than UCEC patients with low PHF6 expression. PHF6 mutation occurred in 12% of UCEC patients, and PHF6 mutation predicted favourable clinical outcome in UCEC patients. Depletion of PHF6 effectively inhibited HEC‐1‐A and KLE cell proliferation in vitro and decreased HEC‐1‐A cell growth in vivo. Furthermore, high PHF6 level indicated a subtype of UCECs characterized by low immune infiltration, such as CD3+ T‐cell infiltration. While knockdown of PHF6 in endometrial carcinoma cells increased T‐cell migration by promoting IL32 production and secretion. Taken together, our findings suggested that PHF6 might play an oncogenic role in UCEC patients. Thus, PHF6 could be a potential biomarker in predicting the prognosis of UCEC patients. Depletion of PHF6 may be a novel therapeutic strategy for UCEC patients.